A phase II study of a candidate COVID-19 vaccine in children (COV006)

Project summary:

The purpose of this study is to test a new vaccine against COVID-19 in children and young adults aged 6-17 years.

This study will enable us to assess if children can be protected from COVID-19 with this new vaccine called ChAdOx1 nCoV-19. It will also give us valuable information on safety aspects of the vaccine and its ability to generate good immune responses against the virus, in children and young people.  We will do this by randomly allocating participants to receive the COVID-19 vaccine or a control injection in addition to doing blood tests and collecting information about any symptoms that occur after vaccination.

Participants from Black, Asian and Minority Ethnic groups are particularly welcomed to participate in this study.


National Institute for Health Research and AstraZeneca

Leader researcher:

Professor Sir Andrew Pollard

Lead institution:

University of Oxford

Vaccine type:


Recruitment for clinical trial open:



COV006 web page